Key facts
- This page summarizes John K. Bakewell's Form 4 filing for Neuronetics, Inc. (STIM).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 26 May 2023, 16:10.
John K. Bakewell - 24 May 2023 Form 4 Insider Report for Neuronetics, Inc. (STIM)
- Reporting relationship
- Director
- Issuer ticker
- STIM
- Reported as of
- 24 May 2023
- Net transaction value
- -$38,880
- SEC form
- 4
- Accepted by SEC
- 26 May 2023, 16:10:40 UTC
- Prior SEC filing
- 25 May 2023
- Next SEC filing
- 17 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ W. Andrew Macan as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John K. Bakewell filed Form 4 for Neuronetics, Inc. (STIM) on 26 May 2023.
Change
- Previous filing in this sequence was filed on 25 May 2023.
- Current net transaction value: -$38,880.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
STIM
transaction
Common Stock
Sale
- Transaction value
- $38,880
- Shares
- -14,400
- Change %
- -16%
- Price
- $2.70
- Shares after
- 77,988
- Date
- 24 May 2023
- Ownership
- Direct
- Footnotes
- F1, F2
STIM
transaction
Common Stock
Award
- Transaction value
- Shares
- +36,364
- Change %
- +47%
- Price
- Shares after
- 114,352
- Date
- 25 May 2023
- Ownership
- Direct
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The sales reported in this Form 4 were pursuant to a 10b5-1 plan validly adopted by the reporting person to cover the reporting person's tax liability from a restricted stock unit ("RSU") award vesting on May 26, 2023.
Footnote F2
The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $2.60 to $2.77. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
Represents an RSU award that vests on the earlier of (a) May 23, 2024, or (b) the reporting person's Board-approved separation of service from the Issuer, in each case subject to continuous service of the reporting person through such date.
Footnote F4
Each RSU represents a contingent right to receive one share of the Issuer's common stock.